Asia Pacific Peripheral Liquid Embolic Agents Market (2026 - 2036)

Asia Pacific Peripheral Liquid Embolic Agents Market Summary

The Asia Pacific peripheral liquid embolic agents market size was valued at USD 40.6 million in 2025 and is projected to grow from USD 44.8 million in 2026 to USD 91.1 million by 2036, at a CAGR of 7.4% from 2026 to 2036. The rising burden of peripheral artery disease and other vascular disorders across Asia Pacific is supporting demand for endovascular interventions. In addition, the growing adoption of minimally invasive vascular procedures is contributing to the use of catheter-based treatment approaches, particularly as healthcare systems emphasize procedures associated with lower procedural morbidity, shorter hospital stays, and faster patient recovery.

The rising burden of varicose veins in Asia Pacific is driving growth in the peripheral liquid embolic agent market, driven by growing demand for minimally invasive venous treatment approaches. Varicose veins, primarily associated with chronic venous insufficiency and malfunctioning venous valves, are becoming an important vascular health concern due to the aging population and increasing need for effective symptom management. The shift from conventional surgical vein stripping toward minimally invasive endovascular procedures has increased the adoption of advanced venous closure technologies. Liquid embolic agents, particularly adhesive-based embolic materials, are gaining attention for enabling non-thermal vein occlusion through controlled delivery and reduced dependence on energy-based ablation techniques. The rising number of patients undergoing treatment for symptomatic varicose veins, along with increasing physician preference for minimally invasive procedures, is creating opportunities for peripheral liquid embolic agents in venous applications.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

For instance, data published by Springer in June 2026 and the 2024 National Clinical Database (NCD) annual report by the Japan Surgical Society indicate that 223,422 peripheral vascular surgical procedures were registered in the NCD in 2024, an increase of more than 2,700 cases compared with 2023. The procedure with the highest number in this category was endovascular treatment for extremity arteries.

To learn more about this report, Download Free Sample Report

Market Dynamics

The Asia Pacific peripheral liquid embolic agents market is supported by the expansion of interventional radiology capabilities, increasing use of embolization in oncology, and growing adoption of image-guided vascular interventions across major markets such as Japan and India. The region's substantial cancer burden is creating greater demand for transarterial and other embolization procedures for hypervascular tumors and preoperative vascular management. In addition, the increasing availability of specialized interventional radiology centers and advanced angiographic technologies is enabling physicians to perform more selective and complex embolization procedures. The use of liquid embolic agents, including NBCA and ethylene vinyl alcohol copolymers, is particularly relevant where deep distal penetration and controlled vascular occlusion are required.

Market Concentration & Characteristics

The market is characterized by a high degree of innovation, supported by ongoing advancements in liquid embolic formulations, delivery systems, radiopacity, viscosity, polymerization characteristics, and catheter compatibility. Manufacturers and clinical users are focused on technologies that provide controlled delivery, predictable vessel occlusion, and improved visualization during image-guided procedures.

The market is characterized by a moderate level of M&A activity, with companies seeking to strengthen their interventional radiology and peripheral vascular portfolios through acquisitions, strategic partnerships, licensing arrangements, and regional distribution agreements. These activities can provide manufacturers with access to complementary embolization technologies, established hospital and distributor networks, specialized clinical expertise, and new geographic markets. M&A and partnership opportunities are particularly relevant in emerging Asia Pacific markets, where local regulatory knowledge and distribution capabilities can accelerate commercialization.

To learn more about this report, Download Free Sample Report

The market experiences a high regulatory impact because products must satisfy country-specific requirements related to safety, performance, clinical evidence, manufacturing quality, registration, and post-market surveillance. Regulatory pathways vary significantly across major markets. China's National Medical Products Administration (NMPA) maintains specific provisions for medical device registration and filing, while India's Central Drugs Standard Control Organization (CDSCO) regulates medical devices under the Medical Devices Rules, 2017. Japan's PMDA and Ministry of Health, Labour and Welfare (MHLW) oversee medical device review, approval, and post-market safety activities. Differences in regulatory requirements across China, Japan, India, Australia, South Korea, and Southeast Asian countries can increase product registration costs, documentation requirements, and time to market.

The market faces moderate to high competition from substitute embolization technologies, including embolization coils, vascular plugs, particles, and other embolic materials. Product selection depends on vessel size, lesion characteristics, vascular anatomy, desired permanence of occlusion, procedural complexity, and physician preference. Coils and vascular plugs are commonly used for focal vessel occlusion, while particles may be preferred for selected tumor embolization and other applications. Liquid embolic agents provide differentiated capabilities, including penetration into distal or complex vascular networks, conformity to irregular vascular anatomy, and the potential for more extensive embolization of interconnected vessels.

Demand for peripheral liquid embolic agents in Asia Pacific is highly concentrated among hospitals, academic medical centers, tertiary care facilities, and specialized interventional radiology and vascular centers. These facilities generally have access to angiography systems, advanced imaging technologies, catheterization laboratories, microcatheters, and trained interventional specialists required for complex embolization procedures. The concentration is particularly strong in high-volume centers in countries such as China, Japan, South Korea, Australia, and India, where interventional radiology capabilities are relatively established.

Analyst Perspective

From an analyst’s perspective, the Asia Pacific peripheral liquid embolic agents market is positioned for steady expansion as healthcare systems strengthen interventional radiology infrastructure and physicians adopt minimally invasive embolization techniques. Market opportunities are expected to be driven by continued innovation in liquid embolic formulations, improved delivery systems, expanding clinical applications, and increasing availability of advanced imaging technologies. Manufacturers with products offering controlled delivery, adequate radiopacity, biocompatibility, and reliable occlusion, supported by strong clinical evidence and regulatory clearances, are likely to gain a competitive advantage. In addition, specialist physician training, development of dedicated vascular centers, and increasing adoption of embolization across hospitals and outpatient facilities are expected to support broader penetration of peripheral liquid embolic agents across major Asia Pacific markets.

Product Type Insights

The Ethylene Vinyl Alcohol Copolymer (EVOH) segment dominated the Asia Pacific peripheral liquid embolic agents market, accounting for 55.6% of the market in 2025. The segment's leading position is supported by the increasing use of non-adhesive liquid embolic agents in complex peripheral vascular procedures, where controlled delivery and distal vessel penetration are important for achieving targeted vascular occlusion. EVOH-based agents can provide more controlled embolization with reduced risk of unintended catheter adhesion compared with adhesive liquid embolics, supporting their use in technically challenging procedures.

Cyanoacrylates / tissue glues combined segment is expected to witness significant growth during the forecast period, driven by the increasing demand for rapid and permanent vascular occlusion in emergency hemorrhage management and high-flow vascular lesions. n-Butyl cyanoacrylate (n-BCA) rapidly polymerizes upon contact with blood, enabling immediate vessel occlusion and making it particularly useful for small-caliber and tortuous vessels where rapid hemostasis is required. For instance, in November 2025, a systematic review of six studies involving 667 patients found that NBCA-based embolization in prostate artery embolization achieved high technical success, with International Prostate Symptom Score (IPSS) improvement reported in 83–94% of patients and no major adverse events reported across the reviewed studies. The availability of n-hexyl cyanoacrylate (n-HCA), which offers slower polymerization and controlled delivery, further expands the application potential of cyanoacrylate-based embolics in small and tortuous vessels.

Application Insights

The venous applications segment dominated Asia Pacific peripheral liquid embolic agents market, accounting for 36.5% of the market in 2025. This dominance is supported by the substantial burden of venous conditions requiring vascular intervention, particularly varicocele. A 2024 systematic review and meta-analysis reported that varicocele was present in 10.9% of men with azoospermia and contributed to 14.8% of male infertility cases. The study also included nine studies and found significant improvements in sperm concentration (SMD: 1.81), progressive sperm motility (SMD: 4.28), and sperm morphology (SMD: 3.59) following varicocele repair. The high prevalence and clinical impact of varicocele support continued demand for minimally invasive venous interventions, including embolization, thereby contributing to the leading position of venous applications in the Asia Pacific peripheral liquid embolic agents market.

The Type II endoleaks segment in Asia Pacific peripheral liquid embolic agents market is expected to grow at the fastest rate during the forecast period, driven by the increasing use of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms and the persistent occurrence of Type II endoleaks following these procedures. Type II endoleaks are the most common type of endoleak and require secondary embolization when associated with persistent blood flow and aneurysm sac enlargement. The growing adoption of minimally invasive endovascular interventions, combined with advances in liquid embolic agents such as ethylene-vinyl alcohol copolymers and n-butyl cyanoacrylate, is supporting the use of embolization for complex endoleaks. Liquid embolic agents can penetrate the endoleak cavity and smaller collateral vessels, providing an important treatment option when selective catheterization of all feeding vessels is difficult.

End Use Insights

The hospitals end use segment dominated the market, accounting for 64.7% in 2025. Increasing investment in hospital infrastructure and the expansion of tertiary and specialized healthcare facilities across Asia Pacific are creating opportunities for the hospital end-use segment. For instance, India's Union Budget 2026–27 allocated INR 4,770 crore (approximately USD 526 million) to the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM), representing a 67.7% increase from the revised allocation of INR 2,845 crore (approximately USD 313 million) in 2025–26. The funding is intended to expand critical care blocks, integrated public health laboratories, district and sub-district hospitals, and other healthcare infrastructure. These investments are expected to expand hospital capacity and strengthen access to advanced diagnostic and interventional services, supporting the adoption of peripheral liquid embolic agents across hospitals in Asia Pacific.

To learn more about this report, Download Free Sample Report

The others end use segment of the Asia Pacific peripheral liquid embolic agents market is expected to grow at the fastest rate during the forecast period. This growth is supported by the increasing adoption of outpatient interventional procedures, office-based laboratories (OBLs), ambulatory surgery centers (ASCs), and specialized vascular treatment facilities. The shift toward outpatient care is particularly relevant in Asia Pacific, where ambulatory surgery infrastructure is expanding in response to rising healthcare costs, chronic disease burden, and demand for shorter hospital stays.

Country Insights

Japan Peripheral Liquid Embolic Agents Market Trends

The Japan peripheral liquid embolic agents market held a significant share in 2025, supported by the country’s rapidly aging population, well-established interventional radiology infrastructure, and broad clinical experience with embolization procedures. Japan has developed clinical guidelines covering several embolization applications, including vascular malformations, portal vein embolization, and vascular access interventions, supporting standardized adoption of image-guided procedures. In addition, the increasing burden of vascular and chronic diseases among older adults and the continued use of endovascular therapies are sustaining demand for advanced embolic technologies, including liquid embolic agents.

India Peripheral Liquid Embolic Agents Market Trends

The India peripheral liquid embolic agents market is witnessing the fastest rate during the forecast period, supported by the substantial burden of chronic venous disorders and increasing recognition of vascular diseases across underserved populations. For instance, a study published by Elsevier Inc in May 2026, titled "prevalence of chronic venous disorders and its risk factors among rural adults in Tamil Nadu, South India," a cross-sectional study was conducted in four rural villages in Tamil Nadu, involving 1,151 participants aged ≥18 years. A two-stage cluster sampling approach was used, selecting one large village from each Primary Health Center area and enrolling all eligible adults from consecutive streets until the sample size was met.

Source: Elsevier 2026

Key Asia Pacific Peripheral Liquid Embolic Agents Company Insights

Some of the key companies in the Asia Pacific peripheral liquid embolic agents market include Medtronic, BALT Group (via Getz Healthcare), GEM S.r.l. (H.B. Fuller), and B. Braun SE. Major players in the Asia Pacific peripheral liquid embolic agents market are focusing on product innovation and development of advanced formulations with improved delivery control, penetration, visibility, and safety.

Key Asia Pacific Peripheral Liquid Embolic Agents Companies

• Medtronic

• BALT Group (via Getz Healthcare)

• GEM S.r.l. (H.B. Fuller Company)

• B. Braun SE

Asia Pacific Peripheral Liquid Embolic Agents Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, Grand View Research has segmented the Asia Pacific peripheral liquid embolic agents market report based on product type, application and end use:

• Product Type Outlook (Revenue, USD Million, 2021 - 2036)

  • Ethylene Vinyl Alcohol Copolymer (EVOH)

  • Cyanoacrylates / tissue glues combined

  • n-butyl cyanoacrylate (n-BCA)

  • n-hexyl cyanoacrylate (n-HCA)

• Application Outlook (Revenue, USD Million, 2021 - 2036)

  • Peripheral Vascular Hemorrhage

  • Hypervascular Tumors

  • Peripheral Vascular Malformations / AVMs

  • Aneurysms / Pseudoaneurysms

  • Type II Endoleaks

  • Portal Vein Embolization (PVE)

  • Venous Applications (varicocele, PCS, varicose veins)

• End Use Outlook (Revenue, USD Million, 2021 - 2036)

  • Hospitals

  • Others

• Country Outlook (Revenue, USD Million, 2021-2036)

  • Japan

  • India

Research Methodology

The Asia Pacific peripheral liquid embolic agents market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each Asia Pacific peripheral liquid embolic agents segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations